SGCG and neoplasm: For stimulating effects, ICIs can induce an enhanced expression of tumor cell ISGs transcribing additional T-cell co-inhibitory ligands (e.g., TNFRSF14, LGALS9) where blockade of type I and II IFN signaling could reverse this effect and improve ICI responses (Benci et al, 2016).